Time magazine this month published an in-depth look at how collaboration is beginning to change the way cancer research is approached, citing numerous examples of the effectiveness of scientists working together to find a cure.
A new blood test technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. Keep reading for more information.
GIST Day of Learning (GDOL), a free event, was held at the University of Miami on Saturday, March 23. Sponsored through the generous support of Bayer, Novartis and Genentech, this event is the second in a series of seminars focusing on the education and support of GIST patients and their families.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
Family planning can be one of the hardest decisions patients with GIST make, but for Carolina Ponce Williams the decision was easy. At high risk for progression, Carolina longed to start a family. So she decided to adopt.
The LRG is continually involved in advocacy efforts to increase government spending on cancer research. We have joined forces with other cancer agencies to once again urge New Jersey Governor Chris Christie and the New [...]
My name is Juliana Popova and I’m the chairperson of the Bulgarian support group for people with GIST – “GIST Alliance for Patients-Bulgaria”. Our organization was founded in January 2012. All patients can contact us [...]
Piga Fernandez, the LRG’s global relations coordinator, participated in an activity called “I have cancer, …lets talk” organized by Red Chile Cancer, a coalition of cancer patient groups in Chile. The main objective [...]
Carol Heller will be working with Jeff Bernstein to cover the state of Pennsylvania as local group leaders. She is very excited to help and hold meetings, and will be handling the eastern region of [...]
Ovarian cancer treatment flaws have been exposed during a recent study, according to an article in the New York Times. The study was conducted by Dr. Robert E. Bristow, director of gynecologic oncology at the University of California, Irvine.
